Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.
End Further Info
Start Supplemental Information
The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of Start Printed Page 3192information unless it displays a currently valid OMB control number.
Table 1—List of Information Collections Approved by OMB
|Title of collection||OMB Control No.||Date approval
|Recommendations for Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use||0910-0583||10/31/2021|
|Guidance for Industry on Controlled Correspondence Related to Generic Drug Development||0910-0797||10/31/2021|
|Guidance for Industry on Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act||0910-0800||10/31/2021|
|Generic Clearance for the Collection of Quantitative Data on Tobacco Products and Communications||0910-0810||10/31/2021|
|MedWatch: Adverse Event and Product Experience Reporting System (Paper-Based)||0910-0291||11/30/2021|
|Electronic User Fee Payment Form Requests||0910-0805||11/30/2021|
|Labeling of Red Blood Cell Units with Historical Antigen Typing Results||0910-0862||11/30/2021|
|Postmarketing Adverse Drug Experience Reporting||0910-0230||12/31/2021|
End Supplemental Information
Dated: February 5, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-01812 Filed 2-8-19; 8:45 am]
BILLING CODE 4164-01-P